Certificate of Analysis (CoA) for Research Peptides — What Every Lab Should Demand

The peptide certificate of analysis is the single most important document a research laboratory will ever receive from a supplier. It is not a marketing flyer, not a generic specification sheet, and not a “purity claim” printed on a vial label. A properly executed peptide certificate of analysis is a lot-specific, signed analytical report that ties a defined quantity of synthesized material to a battery of orthogonal tests, each capable of detecting a different mode of failure. Without it, every downstream experiment — receptor binding studies, in vivo pharmacokinetics, structure-activity work — is built on an unverified assumption.

This guide is written for principal investigators, lab managers, quality assurance officers, and biotech procurement professionals who source research peptides for preclinical work. It walks through every section of a modern peptide certificate of analysis, explains the analytical chemistry behind each test, and provides decision rules for accepting, rejecting, or escalating a lot. It also explains why peptide third-party testing has become the de facto standard for serious laboratories, and why a sub-98% purity result on certain sequences can invalidate an entire study cohort.

Frequently Asked Questions

What is a peptide certificate of analysis?

A peptide certificate of analysis is a lot-specific analytical document issued by the manufacturer or an independent laboratory that reports the results of identity, purity, and safety testing performed on a specific batch of synthesized peptide. It typically includes HPLC chromatograms, mass spectrometry data, water content, counterion content, residual solvent levels, and microbial and endotoxin results. The CoA is the only credible evidence that the material in the vial matches the sequence and purity claimed on the label.

What purity should a research peptide CoA show?

For most preclinical research applications, HPLC peptide testing should report ≥98% area purity, with no single related impurity exceeding 1.0%. For receptor binding, structure-activity relationship studies, or in vivo pharmacology, ≥99% is preferred because closely related deletion or truncation impurities can themselves be biologically active and confound interpretation. Lower purity (95–97%) may be acceptable for crude screening or solubility testing but should never be used for publication-grade data.

Is a CoA the same as a third-party assay?

No. A manufacturer-issued CoA is generated by the supplier’s own analytical chemistry team. Peptide third-party testing, by contrast, is performed by an independent ISO 17025 or GLP-registered laboratory that has no commercial interest in the result. Reputable suppliers routinely send a representative sample of each lot for independent verification and publish the third-party report alongside their internal CoA. Demand both whenever possible.

How do I verify a CoA is authentic?

Cross-check the lot number, manufacture date, and analyst signature against the supplier’s online lot lookup portal. Authentic CoAs are PDF documents with embedded chromatogram images, not editable Word files. The mass spectrometry trace should show the correct monoisotopic mass within ±0.5 Da of theoretical. Any CoA that omits chromatogram images, lists only summary numbers, or cannot be tied to a unique lot identifier should be rejected.

What is peptide batch QA and how is it different from a CoA?

Peptide batch QA is the broader quality assurance program a manufacturer runs across every synthesis batch — encompassing raw material qualification, in-process controls, final release testing, stability monitoring, and deviation handling. The CoA is the output document that summarizes the final release tests for one specific lot. Strong batch QA programs produce defensible CoAs; weak programs produce CoAs that report only the minimum required tests with no traceability to upstream controls.

Why does mass spec peptide analysis matter if HPLC already shows high purity?

HPLC measures relative area under a UV trace and confirms that one major species elutes. It cannot, on its own, prove that species is the intended sequence. Mass spec peptide analysis (typically ESI-MS or MALDI-TOF) measures the molecular weight directly and confirms the identity of the main peak. A peptide can show 99% HPLC purity yet be the wrong sequence entirely — for example a deletion mutant missing one residue that co-elutes with the target. The two techniques are orthogonal and both are required.

What endotoxin limits should I expect on a research peptide CoA?

For in vitro cell culture work, an endotoxin limit of <1 EU/mg is typically sufficient. For in vivo rodent studies, <0.5 EU/mg is preferred, and for any work approaching translational relevance, <0.1 EU/mg is the benchmark. The CoA should specify the assay used (LAL gel-clot, kinetic chromogenic, or recombinant Factor C) and the detection limit, not just a pass/fail.

Can a CoA be reissued or amended?

Yes, but every amendment must be flagged with a revision number, a date, and a description of the change. A CoA that is silently updated without versioning is a major quality red flag. Reputable suppliers maintain a full revision history accessible to customers on request. If you are running long-term studies, archive the exact CoA version you received at the time of purchase.

What a peptide certificate of analysis actually is

A peptide certificate of analysis is a controlled quality document, generated under a defined quality management system, that ties one specific synthesized lot to a battery of analytical results. It is the bridge between the synthesis chemist who made the material and the researcher who will use it in a cell culture flask or animal model. Without that bridge, the researcher is trusting the label on the vial — and labels lie, fade, get switched, and get printed before the analytical chemistry team has even run the tests.

The peptide certificate of analysis serves four distinct functions. First, it documents identity: this lot is in fact the sequence on the label. Second, it documents purity: this lot is at least the stated percent of the intended species, with related impurities quantified and limited. Third, it documents safety: this lot meets specifications for endotoxin, bioburden, residual solvents, and heavy metals appropriate to the intended use. Fourth, it documents traceability: this lot can be tied back to specific raw materials, synthesis records, and the analyst who released it.

The legal and regulatory framing

Research peptides sold for laboratory use are not pharmaceutical products and are not regulated as drugs by the FDA or the EMA. They are, however, often regulated as chemicals under jurisdictional hazardous-materials, controlled-substance, or research-chemical frameworks. The CoA is the primary document a customs officer, institutional biosafety committee, or grant auditor will request to verify that a shipment is what it claims to be. A missing or defective CoA can stop a shipment at the border, freeze an IACUC protocol, or trigger an institutional audit.

The reproducibility crisis dimension

The biomedical reproducibility crisis has many drivers, but uncharacterized reagents — including peptides — are repeatedly cited in failure-mode analyses. A 2015 analysis published via the NCBI literature reported that a substantial fraction of irreproducible preclinical results could be traced to reagent variation between lots. Insisting on peptide purity verification through a documented CoA is one of the cheapest, highest-leverage interventions a lab can make to improve the durability of its data.

The anatomy of a defensible CoA: section by section

A well-constructed peptide certificate of analysis contains, at minimum, the sections described below. The order may vary between manufacturers but the content should not. If any of these elements is missing, the document is incomplete and the lot should not be released for sensitive experiments without follow-up.

Header and identification block

The header carries the supplier name, address, and contact for quality questions; the product name and catalog number; the unique lot number; the manufacture date; the expiry or retest date; the storage conditions; the quantity; and the name and signature of the releasing analyst. Each of these fields is auditable. The lot number is the key that unlocks every downstream record — synthesis logs, raw material lots, in-process tests, stability data. A CoA without a unique lot number is not a CoA; it is a marketing document.

Sequence and theoretical properties

The CoA must state the full one-letter or three-letter amino acid sequence, all modifications (acetylation, amidation, cyclization, disulfide bonds, PEGylation, lipidation), and the theoretical molecular weight (both monoisotopic and average). It should also note the salt form (typically trifluoroacetate, acetate, or hydrochloride) and the theoretical net peptide content, which differs from gross weight because the counterion and bound water contribute mass that is not peptide.

Identity confirmation

Identity is confirmed by mass spec peptide analysis. The CoA should reproduce the deconvoluted mass spectrum and report the observed mass alongside the theoretical mass. Acceptance criteria are typically observed within ±0.5 Da of theoretical for ESI-MS and ±1 Da for MALDI-TOF on peptides under 5 kDa. For larger peptides or those with complex modifications, higher tolerances may be appropriate but must be defined in advance.

Purity by HPLC

HPLC peptide testing is the workhorse purity assay. The CoA should reproduce the chromatogram, identify the main peak by retention time, report area percent purity, and list each impurity peak above the reporting threshold (typically 0.1% area). Method conditions — column chemistry, mobile phase composition, gradient, flow rate, detection wavelength, injection volume — must be stated so that the result can be reproduced. A purity number without method conditions is meaningless.

Water content

Water content is measured by Karl Fischer titration and is critical for accurate concentration calculations. A peptide lot reporting 8% water content means that 1 mg of solid contains only 0.92 mg of dry material before accounting for counterion and impurities. Ignoring water content can produce 10–15% systematic concentration errors that propagate through every experiment in the cohort.

Counterion content

Most synthesized peptides are isolated as trifluoroacetate (TFA) salts from the final reversed-phase HPLC purification step. The CoA should report counterion content by ion chromatography or NMR. TFA content above 10% can interfere with cell-based assays, especially mitochondrial readouts; acetate exchange is available from most suppliers for sensitive applications and should itself be documented on a revised CoA.

Net peptide content

Net peptide content is the gross weight minus water, counterion, and non-peptide impurities. It is the number researchers should use for concentration calculations. Reporting only HPLC purity without net peptide content is a common shortcut that introduces 5–20% concentration errors. A defensible CoA reports both.

Residual solvents and heavy metals

Synthesis uses solvents — DMF, NMP, DCM, acetonitrile, methanol, ether — and reagents that can leave trace residues. The CoA should report residual solvent content by headspace gas chromatography against ICH Q3C Class 1, 2, and 3 limits. Heavy metals testing (ICP-MS for Pb, Cd, As, Hg) is appropriate for any lot intended for in vivo work.

Microbial limits and endotoxin

Bioburden (total aerobic microbial count, total combined yeast and mold count) and endotoxin (LAL or recombinant Factor C assay) are essential for any lot used in cell culture or animal work. The CoA should state the limit, the result, and the method. Endotoxin contamination is invisible at the milligram scale but can completely confound immunology and inflammation studies at picogram levels.

HPLC peptide testing: reading the chromatogram

HPLC peptide testing is performed on reversed-phase columns, typically C18 or C8 with 100–300 Å pore size depending on peptide length. The mobile phase is a binary gradient of water and acetonitrile, both modified with 0.1% trifluoroacetic acid or formic acid to suppress secondary interactions with residual silanols. Detection is by UV absorbance at 214 nm (peptide bond) or 220 nm. The CoA should show the full chromatogram, not just a thumbnail, with a clear baseline and labeled peaks.

Method orthogonality

A single HPLC method can be fooled by co-eluting impurities. Best-practice peptide purity verification runs two orthogonal HPLC methods — for example, a TFA-modified gradient and a formic-acid-modified gradient, or a C18 method and an HILIC method. If both report ≥98% area purity, confidence in the result is high. If they disagree by more than 1–2%, the lower number should be considered the true purity and the discrepancy investigated.

Related impurities

The impurities that matter most are deletion sequences (one residue missing), truncation sequences (chain ended early), oxidation products (methionine, tryptophan, or cysteine oxidized), and diastereomers (one residue racemized during coupling). The CoA should ideally name each impurity above the qualification threshold and explain its origin. Generic “unknown impurity at RT 12.4 min, 0.8%” is acceptable but less informative than “des-Gly impurity, 0.8%.”

Compounds with high impurity sensitivity

Certain peptides are exquisitely sensitive to closely related impurities. The 15-residue gastric pentadecapeptide BPC-157, for example, has been studied in numerous models of tissue repair; deletion impurities can confound binding studies. TB-500, the synthetic fragment of thymosin beta-4, has multiple oxidation-prone residues that can degrade during storage if not properly characterized. The copper-binding tripeptide-derivative GHK-Cu requires explicit copper stoichiometry reporting on its CoA, not just purity by HPLC.

Mass spec peptide analysis: confirming identity

Mass spectrometry is the orthogonal technique that confirms what HPLC has purified. The two dominant ionization techniques in peptide chemistry are electrospray ionization (ESI-MS) and matrix-assisted laser desorption/ionization (MALDI-TOF). Both are routinely reported on a research-grade CoA.

ESI-MS

ESI generates multiply-charged ions in solution, which are then deconvoluted to give the neutral monoisotopic mass. For peptides under 5 kDa, modern Orbitrap or Q-TOF instruments routinely deliver sub-ppm mass accuracy. The CoA should report the observed deconvoluted mass and the mass error in parts per million or Daltons.

MALDI-TOF

MALDI-TOF embeds the analyte in a UV-absorbing matrix (typically α-cyano-4-hydroxycinnamic acid for peptides) and uses a laser pulse to desorb and ionize. It is faster than ESI for routine screening and tolerates more sample-matrix variability, but mass accuracy is lower (typically tens of ppm). It is excellent for confirming the dominant species in a sample but less suited to quantifying low-abundance impurities.

Tandem MS for sequence confirmation

For long peptides or those with complex modifications, MS/MS fragmentation (CID, HCD, or ETD) generates a sequence-informative ladder of b- and y-ions that confirms the full primary structure. This is particularly important for GLP-1 analogs, GHRH analogs like tesamorelin, and multi-agonist constructs such as retatrutide, where a single deletion or substitution can dramatically alter receptor selectivity. MS/MS data is increasingly standard on premium CoAs.

Comparison of CoA quality tiers

Not all peptide certificates of analysis are created equal. The following table summarizes the tiers commonly encountered in the research market.

Most academic in vitro work is well served by the standard or premium tier. In vivo pharmacology should not be conducted with anything below publication-grade material backed by a defensible peptide certificate of analysis.

Peptide purity verification: orthogonal techniques

Peptide purity verification rests on the principle that no single analytical technique catches every failure mode. HPLC counts UV-absorbing species but cannot distinguish a peptide from a similarly-sized non-peptide contaminant. Mass spec confirms molecular weight but says nothing about stereochemistry. Amino acid analysis quantifies bulk composition but cannot resolve sequence isomers. A serious CoA reports at least two orthogonal techniques; a translational-grade CoA reports four or more.

Amino acid analysis (AAA)

AAA hydrolyzes the peptide to its constituent free amino acids (typically with 6N HCl at 110 °C for 24 h) and quantifies each by ion-exchange chromatography with ninhydrin detection or by reversed-phase HPLC after derivatization. The result is a molar ratio of each amino acid that should match the theoretical composition. AAA also provides an absolute quantification of net peptide content that does not depend on HPLC area assumptions.

Capillary electrophoresis

Capillary electrophoresis (CE) separates peptides by charge-to-size ratio in an electric field. It is orthogonal to reversed-phase HPLC because it depends on different physicochemical properties. Some publication-grade CoAs include a CE purity result alongside HPLC for high-confidence verification.

NMR spectroscopy

One- and two-dimensional NMR is rarely included on routine CoAs because it requires substantial sample (typically several milligrams) and specialist interpretation. For specialty peptides, however — cyclic peptides, peptides with non-standard amino acids, or peptides where stereochemistry of a critical residue must be confirmed — NMR is the gold-standard identity test.

Peptide third-party testing: when and why

Peptide third-party testing means sending a sample of a manufactured lot to an independent ISO 17025 or GLP-registered analytical laboratory for blinded re-analysis. The third-party lab has no commercial relationship with either the buyer or the seller and no incentive to flatter the result.

What third-party testing catches

Third-party testing catches three categories of failure that internal CoAs sometimes miss. First, instrument calibration drift — an internal HPLC running slightly out of spec can systematically overstate purity. Second, method bias — an internal method optimized to make a particular impurity invisible. Third, deliberate misreporting — at the worst end of the spectrum, fabricated CoAs from disreputable suppliers.

How to request third-party verification

For high-stakes work, request that the supplier ship a small aliquot of the lot directly to a named third-party laboratory of your choice, and ask the third-party lab to send the result directly to you. This breaks the chain-of-custody back to the supplier and produces an independent, defensible analytical record. The cost is typically modest — a few hundred dollars per lot — and is trivial compared to the cost of a failed in vivo study.

Industry norms

The leading research peptide suppliers have moved toward routine third-party verification of every lot, with the third-party CoA published alongside the internal CoA on the product page. This trend is being driven by institutional procurement requirements at major research universities and by funding agencies that increasingly require documented reagent provenance in grant reports.

Peptide batch QA: the program behind the document

Peptide batch QA is the manufacturer’s broader quality program. The CoA is the visible output, but the credibility of the CoA depends entirely on the program behind it. A research lab evaluating a new supplier should ask for and review the following peptide batch QA elements.

Raw material qualification

Every Fmoc-amino acid, resin, coupling reagent, and solvent used in synthesis should be qualified against a supplier specification and tested on receipt. The CoA on the final peptide is only as defensible as the CoAs on the raw materials that went into it.

In-process controls

During synthesis, in-process controls — Kaiser test for free amines, analytical HPLC of the crude peptide before purification, monitoring of deprotection efficiency — flag problems early. Manufacturers with mature batch QA programs document these checkpoints and can produce them on audit.

Out-of-specification (OOS) handling

When a lot fails a specification, what happens next is a window into the supplier’s quality culture. Mature programs have written OOS procedures: investigation, root-cause analysis, decision to release with deviation, reject the lot, or rework. A supplier who cannot describe their OOS process clearly is a supplier whose CoAs cannot be fully trusted.

Stability and retest dates

Peptides degrade. Stability programs generate the data behind the retest date on the CoA. Real-time stability data at the labeled storage condition (typically -20 °C or -80 °C for lyophilized powder) should be available on request. For a deeper discussion of post-receipt handling, see our peptide reconstitution lab protocol.

Red flags on a peptide certificate of analysis

Experience teaches researchers to recognize CoA red flags. The following list summarizes the most common problems.

• Missing lot number or a lot number that does not match the vial label.
• No chromatogram images — only summary numbers in a table.
• Editable file formats (Word, Excel) rather than locked PDF.
• Purity stated to three decimal places on a single method — false precision.
• Mass spectrum not shown, only a single observed mass number reported.
• No method conditions for HPLC — column, gradient, detection wavelength missing.
• No water content or counterion content — net peptide content cannot be calculated.
• No endotoxin result on a lot intended for in vivo use.
• Manufacture date predates synthesis paperwork — sometimes catches fabricated CoAs.
• No analyst name or signature — accountability is missing.
• Identical CoAs across multiple lots — suggests copy-paste rather than per-lot analysis.
• Refusal to provide raw data on request — major escalation trigger.

Storage, stability, and the CoA’s retest date

Every peptide certificate of analysis carries a retest or expiry date. This date is not arbitrary — it is set based on the manufacturer’s stability data for that peptide class at the labeled storage condition. After the retest date, the lot is not automatically expired; it is, however, no longer guaranteed without re-testing.

Lyophilized powder stability

Most research peptides are shipped as lyophilized white powder. At -20 °C in a sealed vial with desiccant, most sequences are stable for 24 months or more. Hygroscopic peptides, peptides with oxidation-prone residues (Met, Cys, Trp), and peptides containing aspartate-glycine motifs (prone to isomerization) may have shorter shelf lives.

Reconstituted solution stability

Once reconstituted, peptide stability is dramatically reduced. Aqueous solutions at neutral pH typically retain potency for one to four weeks at 4 °C, depending on sequence. Freeze-thaw cycles accelerate degradation. The CoA does not cover reconstituted material — that becomes the responsibility of the receiving laboratory.

Re-CoA after long storage

For lots held beyond the retest date that the lab still wishes to use, the responsible course is to re-test by HPLC and mass spec before deploying in critical experiments. Reputable suppliers will perform this re-test for a fee and issue an updated CoA reflecting the new analytical date.

CoA economics: why quality is cheaper than reprocessing data

Researchers sometimes balk at the price differential between a tier-1 crude peptide and a tier-4 publication-grade lot with full peptide third-party testing. The differential can be 3–10× on a per-milligram basis. The relevant comparison, however, is not price-per-milligram — it is total experimental cost.

The hidden cost of low-purity material

A failed in vivo cohort, traced back to an uncharacterized impurity in a research peptide, can cost tens of thousands of dollars in animal costs, technician time, and reagents. A retracted paper costs reputation and grant credibility. A failed grant application costs the next two years of lab funding. Against these costs, the marginal expense of a properly characterized peptide with a defensible CoA is trivial.

Time-to-publication

Beyond direct costs, the time saved by working with well-characterized material is substantial. Experiments produce cleaner data, statistical power improves, and reviewers do not ask for repeated runs to address reagent quality concerns. For comprehensive supplier selection criteria, see our guide on where to buy research peptides in 2026.

Practical CoA review workflow for receiving labs

The following workflow distills the recommendations above into a sequence a receiving laboratory can apply to every incoming peptide lot.

1. Pre-shipment. Request the CoA before the lot ships. Reject the shipment in advance if the CoA does not meet your specification.
2. On receipt. Verify lot number on the vial against the CoA. Verify the seal is intact and the cold-chain indicator (if applicable) has not triggered.
3. Document control. Archive the PDF CoA in your laboratory information management system tagged with the lot number, receipt date, and the experiment cohort it will support.
4. Critical review. Verify HPLC purity meets your spec; verify mass spec observed mass within tolerance; verify endotoxin and microbial within spec; verify water and counterion reported for accurate dosing.
5. Net peptide calculation. Recalculate concentrations using net peptide content, not gross weight.
6. Escalation. Any out-of-spec or missing element escalates to QA. Do not deploy the lot until resolved.
7. End-of-study archive. Retain the CoA for the full retention period required by your institution and any funding agency — typically 7–10 years.

Special cases: when CoAs require extra scrutiny

GLP-1 receptor agonists and incretin multi-agonists

Long-acting incretin analogs and multi-agonist constructs such as retatrutide contain non-standard amino acids and lipidation that complicate both synthesis and analysis. The CoA should explicitly document the fatty acid chain and the attachment point, ideally with MS/MS confirmation. Closely related impurities in this class can have dramatically different receptor selectivity profiles.

GHRH analogs

Growth hormone-releasing hormone analogs such as tesamorelin are 44-residue peptides — long enough that synthesis impurities, particularly deletion sequences, are nontrivial to resolve from main product by single-method HPLC. Dual-method peptide purity verification and MS/MS are strongly recommended for any GHRH analog used in publication-grade work. Background on GHRH research can be found on the PubMed tesamorelin search.

Cyclic and disulfide-bridged peptides

Peptides with intramolecular disulfide bonds (somatostatin analogs, oxytocin analogs) or head-to-tail cyclization require explicit confirmation of the correct ring structure. A linear peptide with the right molecular weight can have identical mass but no biological activity. The CoA should note the cyclization and ideally show evidence of the correct disulfide pattern by mass spec after partial reduction or by NMR.

Copper- and metal-coordinated peptides

The tripeptide GHK-Cu is sold as a copper complex. The CoA must report copper stoichiometry, not just peptide purity. A 1:1 GHK:Cu molar ratio is the target; deviations indicate either incomplete coordination or excess free copper, both of which alter biological behavior.

The future of peptide CoAs: digitization and on-chain provenance

The CoA is evolving. Several developments worth tracking are shaping how research peptide quality will be documented in the next five years.

Machine-readable CoAs

Several major industry working groups are developing XML and JSON CoA schemas that allow analytical results to be ingested directly into laboratory information systems. This eliminates manual transcription errors and enables automated specification checking on receipt.

Digital signatures and tamper evidence

Cryptographically signed PDFs with embedded tamper-evident hashes are becoming standard among the top tier of research peptide suppliers. These prevent post-issuance editing and create an audit-defensible chain of custody.

Blockchain provenance

Several research-chemical suppliers are experimenting with blockchain-anchored provenance, where every CoA, raw material lot, and synthesis record is hashed onto a distributed ledger. Whether this becomes mainstream or remains a niche differentiator is unclear, but the underlying principle — immutable, auditable analytical history — is sound.

Real-time CoA portals

Modern suppliers offer customer portals where a CoA can be looked up by lot number and downloaded directly, eliminating the risk of forwarded or altered PDFs. Always verify the CoA you received against the portal version before relying on a lot for critical work.

Key takeaways

• A peptide certificate of analysis is a lot-specific, signed analytical document, not a generic specification sheet.
• Demand HPLC peptide testing at ≥98% area purity by at least one method; ≥99% by dual orthogonal methods for publication-grade work.
• Require mass spec peptide analysis confirming observed mass within ±0.5 Da of theoretical; MS/MS for complex peptides.
• Insist on net peptide content, water content, and counterion content so concentration calculations are accurate.
• For in vivo work, require endotoxin <0.5 EU/mg and full residual solvent and heavy metal data.
• Insist on peptide third-party testing for high-stakes lots; ISO 17025 or GLP-registered labs only.
• Evaluate the supplier’s peptide batch QA program — raw material qualification, in-process controls, OOS handling, stability data.
• Reject CoAs that lack chromatograms, lot numbers, analyst signatures, or method conditions.
• Archive every CoA for the full retention period required by your institution and funder.
• The marginal cost of premium peptide purity verification is trivial compared to the cost of failed experiments and retracted papers.

Related research from Axion

• Complete Guide to Research Peptides 2026 — foundational reference covering peptide classes, synthesis, and laboratory handling.
• Peptide Reconstitution Lab Protocol — step-by-step procedure for reconstituting lyophilized peptides without compromising stability or sterility.
• Where to Buy Research Peptides in 2026 — supplier evaluation framework including CoA, third-party testing, and provenance requirements.

A defensible peptide certificate of analysis is the single most important document a research peptide supplier can provide. It is the bridge between synthesis and experiment, the evidence behind every concentration calculations, the foundation of every published result. Demand a full peptide certificate of analysis with HPLC chromatograms, mass spec confirmation, net peptide content, endotoxin testing, and lot-specific traceability for every lot. Where the experiment matters, demand peptide third-party testing on top. The cost is trivial; the consequences of skipping it are not.

Disclaimer: These products are sold strictly for laboratory research purposes only. Not for human consumption, diagnosis, or treatment. Statements have not been evaluated by the FDA, EMA, or any regulatory agency. Researchers must comply with all applicable laws and institutional review requirements.